SB
REGN icon

SIG Brokerage’s Regeneron Pharmaceuticals REGN Stock Holding History

SIG Brokerage’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$773K Buy
+1,000
New +$766K 0.02% 467
2025
Q3 		– Sell
-5,700
Closed -$2.99M – 924
2025
Q2 		$2.99M Buy
+5,700
New +$3.18M 0.08% 171

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SIG Brokerage's REGN Position: Q1 2025 in Review

SIG Brokerage sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 1,064 shares — an estimated $732K sold.

SIG Brokerage first reported a position in REGN in Q4 2024 and held it in 1 quarter. The position peaked at $758K in Q4 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • SIG Brokerage reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • SIG Brokerage sold 1,064 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $732K.
  • SIG Brokerage first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • SIG Brokerage's Regeneron Pharmaceuticals position peaked at $758K in Q4 2024.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on SIG Brokerage's 13F filing for Q1 2025, filed 14 May 2025.